次世代エネルギー産業・グリーン経済の国際リサーチ情報サイト

核医学・放射性医薬品の世界市場:2024年に至るタイプ別、用途別予測

Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET- F-18), Therapeutic (Beta Emitters – I-131, Alpha Emitters, Brachytherapy – Y-90)), Application (Oncology, Cardiology) - Global Forecast to 2024

出版元:MarketsandMarketsLinkIcon出版元について
発行年:2020年1月
定価 Single User License(1名様ライセンス)US$5,650(米国ドル)/Multi User License(5名様)$6,650 /Corporate User License $8,150
ご予算に応じた各種ご提案も承ります。詳細はお問い合わせください。
ご請求は円換算(お見積り日TTSレート)となります。
納品形態:PDF by Email
当調査レポートは英文231ページになります。
商品コード:MAM1852

お問い合わせ、お見積りのリクエストは下のボタンをクリックしてご入力ください。



【レポート紹介】
核医学の世界市場規模は2019年で41億ドル、この先2024年は52億ドルに増加すると予測されます。当レポートでは、2024年に至る核医学・放射性医薬品の世界市場予測(市場規模US$)、タイプ別市場(診断用核医学各種、治療用核医学各種)、用途別市場(診断用途各種、治療用途各種)処置数予測(診断処置各種、治療処置各種)、主要国地域別市場など、各種の予測データに基づき市場を展望しています。また市場動向、競合状況、主要企業プロフィールなどの分析も交えて、概略以下の構成でお届けいたします。

【レポート構成概要】
◆核医学・放射性医薬品の世界市場予測2017-2024年
・市場規模(US$)

◆タイプ別、市場-2024年
<診断用核医学>
SPECT用放射性医薬品
・99m Tc
・123I
・201Tl
・67Ga
・その他SPECT同位体

PET用放射性医薬品
・18F
・82Rb
・その他PET同位体

<治療用核医学>
α放射体
・223Ra

β放射体
・131I
・90Y
・153Sm
・177Lu
・186Re
・その他β放射体

密封小線源治療同位体
・125I
・192Ir
・103Pd
・131Cs
・その他密封小線源治療同位体
※(市場規模US$)

◆用途別、市場-2024年
<診断用途>
SPECT
・心臓病学
・骨スキャン
・甲状腺
・肺スキャン
・その他のSPECT用途

PET
・腫瘍学
・心臓病学
・神経学
・その他PET用途

<治療用途>
甲状腺
転移性骨腫瘍
内分泌腫瘍
リンパ腫
その他治療用途
※(市場規模US$)

◆核医学・放射性医薬品、処置数予測-2024年
診断処置
・SPECT
・PET
治療処置
・β放射体
・α放射体
・小線源治療同位体
※処置数データ掲載 

◆主要国地域別市場-2024年
北米
・米国、カナダ
アジア太平洋
・日本、中国
・その他アジア太平洋
欧州
・ドイツ、フランス、英国
・イタリア、スペイン
・その他欧州
その他地域
※地域別に全セグメントの細分化データ掲載
※国別にタイプ別、用途大分類別の細分化データ掲載、詳細は目次参照

◆市場分析
・市場ダイナミクス分析(ドライバー、障壁、機会、課題)
・市場シェア分析
・競合状況

◆核医学・放射性医薬品の主要企業プロフィール動向
・CARDINAL HEALTH  
・CURIUM        
・GE HEALTHCARE      
・LANTHEUS MEDICAL IMAGING, INC.
・BAYER AG     
・BRACCO IMAGING S.P.A.       
・ECZACIBAŞI-MONROL NUCLEAR PRODUCTS
・NORDION, INC. (A SUBSIDIARY OF STERIGENICS INTERNATIONAL)  
・ADVANCED ACCELERATOR APPLICATIONS (AAA) (A PART OF NOVARTIS)             
・NTP RADIOISOTOPES SOC, LTD.
(A SUBSIDIARY OF SOUTH AFRICAN NUCLEAR ENERGY CORPORATION)             
・JOINT STOCK COMPANY ISOTOPE (JSC ISOTOPE)     
・NORTHSTAR MEDICAL RADIOISOTOPES, LLC            
・ECKERT & ZIEGLER  
・JUBILANT DRAXIMAGE, INC. (A SUBSIDIARY OF JUBILANT PHARMA)
・PHARMALOGIC         
・INSTITUTE OF ISOTOPES CO., LTD.  
・SINOTAU PHARMACEUTICALS GROUP          
・ISOTOPIA MOLECULAR IMAGING LIMITED   
・SHINE MEDICAL TECHNOLOGIES     
・GLOBAL MEDICAL SOLUTIONS, LTD.
(全231頁)


【レポート詳細目次、データ項目一覧は当ページ下を参照ください】

英文詳細目次(table of contents)

【原文詳細目次】

Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET- F-18), Therapeutic (Beta Emitters – I-131, Alpha Emitters, Brachytherapy – Y-90)), Application (Oncology, Cardiology) - Global Forecast to 2024

Table of Contents

1.... INTRODUCTION

1.1             OBJECTIVES OF THE STUDY
1.2             MARKET DEFINITION
1.2.1              MARKET SCOPE
1.2.2              MARKETS COVERED
1.2.3              YEARS CONSIDERED FOR THE STUDY
1.3             CURRENCY
1.4             LIMITATIONS
1.5             STAKEHOLDERS

2.... RESEARCH METHODOLOGY

2.1             RESEARCH DATA
2.2             RESEARCH METHODOLOGY STEPS
2.2.1              SECONDARY DATA
2.2.1.1            SECONDARY SOURCES
2.2.2              PRIMARY DATA
2.2.2.1            PRIMARY SOURCES
2.2.2.2            KEY INSIGHTS FROM PRIMARY SOURCES
2.2.3              MARKET SIZE ESTIMATION METHODOLOGY
2.2.4              REVENUE MAPPING-BASED MARKET ESTIMATION
2.3             MARKET DATA ESTIMATION AND TRIANGULATION
2.4             ASSUMPTIONS OF THE STUDY

3.... EXECUTIVE SUMMARY

4.... PREMIUM INSIGHTS

4.1             NUCLEAR MEDICINE MARKET OVERVIEW
4.2             NORTH AMERICA: NUCLEAR MEDICINE MARKET, BY TYPE AND COUNTRY (2019)
4.3             DIAGNOSTIC PROCEDURES MARKET, BY TYPE, 2019 VS. 2024
4.4             THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2019 VS. 2024

5.... MARKET OVERVIEW

5.1             INTRODUCTION
5.2             MARKET DYNAMICS
5.2.1              DRIVERS
5.2.1.1            INCREASING INCIDENCE AND PREVALENCE OF TARGET CONDITIONS
5.2.1.2            ALPHA RADIOIMMUNOTHERAPY-BASED TARGETED CANCER TREATMENT
5.2.1.3            INITIATIVES TO REDUCE THE DEMAND-SUPPLY GAP OF MO-99

5.2.2              RESTRAINTS
5.2.2.1            SHORT HALF-LIFE OF RADIOPHARMACEUTICALS
5.2.3              OPPORTUNITIES
5.2.3.1            USE OF RADIOPHARMACEUTICALS IN NEUROLOGICAL APPLICATIONS
5.2.4              CHALLENGES
5.2.4.1            HOSPITAL BUDGET CUTS AND HIGH EQUIPMENT PRICES

6.... NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY TYPE

6.1             INTRODUCTION
6.2             DIAGNOSTIC NUCLEAR MEDICINE
6.2.1              SPECT RADIOPHARMACEUTICALS
6.2.1.1            TC-99M
6.2.1.1.1            TC-99M COMMANDED THE LARGEST SHARE OF THE SPECT RADIOPHARMACEUTICALS MARKET IN 2018
6.2.1.2            I-123
6.2.1.2.1            REDUCED EXPOSURE TO RADIATION AND LOWER RISK OF PATIENTS DEVELOPING RADIATION-INDUCED CANCER TO DRIVE THE DEMAND FOR I-123
6.2.1.3            TL-201
6.2.1.3.1            TI-201 CAN BE A POTENTIAL SUBSTITUTE TO TC-99M
6.2.1.4            GA-67
6.2.1.4.1            OVERALL SENSITIVITY OF A GALLIUM SCAN IS APPROXIMATELY 80% AS A TUMOR-IMAGING AGENT, WHICH IS A KEY FACTOR DRIVING THE GROWTH OF THE GA-67 MARKET
6.2.1.5            OTHER SPECT ISOTOPES
6.2.2              PET RADIOPHARMACEUTICALS
6.2.2.1            F-18
6.2.2.1.1            F-18 COMMANDED THE LARGEST SHARE OF THE PET RADIOPHARMACEUTICALS MARKET
6.2.2.2            RB-82
6.2.2.2.1            INCREASING NUMBER OF PET PROCEDURES AND HIGH ACCURACY OFFERED BY THE RB-82 ISOTOPE TO DRIVE THE GROWTH OF THIS MARKET
6.2.2.3            OTHER PET ISOTOPES
6.3             THERAPEUTIC NUCLEAR MEDICINE
6.3.1              ALPHA EMITTERS
6.3.1.1            RA-223
6.3.1.1.1            EASY PRODUCTION OF RA-223 IS A KEY ADVANTAGE DRIVING MARKET GROWTH
6.3.2              BETA EMITTERS
6.3.2.1            IODINE-131
6.3.2.1.1            IODINE-131 ACCOUNTED FOR THE LARGEST SHARE OF THE BETA EMITTERS MARKET

6.3.2.2            Y-90
6.3.2.2.1            INCREASING APPLICATIONS IN TREATING HEPATOCELLULAR CARCINOMA TO PROPEL THE GROWTH OF THIS SEGMENT
6.3.2.3            SM-153
6.3.2.3.1            INCREASING INCIDENCE OF BONE METASTASIS TO DRIVE THE GROWTH OF THIS SEGMENT
6.3.2.4            LU-177
6.3.2.4.1            INCREASING INCIDENCE OF NEUROENDOCRINE CANCER IS A KEY FACTOR DRIVING THE GROWTH OF THIS SEGMENT
6.3.2.5            RE-186
6.3.2.5.1            RE-186 IS COMMONLY USED FOR BONE PAIN RELIEF
6.3.2.6            OTHER BETA EMITTERS
6.3.3              BRACHYTHERAPY ISOTOPES
6.3.3.1            IODINE-125
6.3.3.1.1            I-125 ACCOUNTED FOR THE LARGEST SHARE OF THE BRACHYTHERAPY ISOTOPES MARKET
6.3.3.2            IRIDIUM-192
6.3.3.2.1            IR-192 IS USED IN TREATING PROSTATE CANCER, SKIN CANCER, SARCOIDS, AND ORAL CANCER
6.3.3.3            PALLADIUM-103
6.3.3.3.1            PD-103 IS BEST SUITED TO TREAT AGGRESSIVE TUMORS
6.3.3.4            CESIUM-131
6.3.3.4.1            CS-131 IS COMMONLY USED IN GYNECOLOGICAL APPLICATIONS
6.3.3.5            OTHER BRACHYTHERAPY ISOTOPES

7.... NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY APPLICATION

7.1             INTRODUCTION
7.2             DIAGNOSTIC APPLICATIONS
7.2.1              SPECT APPLICATIONS
7.2.1.1            CARDIOLOGY
7.2.1.1.1            RISING INCIDENCE OF CVD HAS INCREASED THE DEMAND FOR CARDIAC DIAGNOSTIC SCANS
7.2.1.2            BONE SCANS
7.2.1.2.1            PRECISION OF SPECT IN BONE SCANNING HAS DRIVEN DEPENDENCE ON THE TECHNOLOGY
7.2.1.3            THYROID APPLICATIONS
7.2.1.3.1            INTRODUCTION OF DUAL SPECT/CT IMAGING IS AN IMPORTANT TREND IN THE THYROID APPLICATIONS SEGMENT
7.2.1.4            PULMONARY SCANS
7.2.1.4.1            SPECT/CT HAS SHOWN HIGH ACCURACY AND SENSITIVITY IN PULMONARY EMBOLISM APPLICATIONS
7.2.1.5            OTHER SPECT APPLICATIONS

7.2.2              PET APPLICATIONS.. 102
7.2.2.1            ONCOLOGY
7.2.2.1.1            INCREASING CANCER INCIDENCE WILL FUEL MARKET GROWTH
7.2.2.2            CARDIOLOGY
7.2.2.2.1            GROWING PREFERENCE FOR FDG IN CARDIAC IMAGING IS LIKELY TO BOOST MARKET GROWTH
7.2.2.3            NEUROLOGY
7.2.2.3.1            INCREASING INCIDENCE OF AD, EPILEPSY, AND PARKINSON’S DISEASE IS THE MAJOR DRIVER FOR THE GROWTH OF THE PET NEUROLOGY MARKET
7.2.2.4            OTHER PET APPLICATIONS
7.3             THERAPEUTIC APPLICATIONS
7.3.1              THYROID INDICATIONS
7.3.1.1            INCREASING PREVALENCE OF THYROID DISORDERS WILL FUEL MARKET GROWTH.. 106
7.3.2              BONE METASTASIS.. 107
7.3.2.1            INTRODUCTION OF NOVEL THERAPIES FOR BONE METASTASIS WILL POSITIVELY IMPACT THE MARKET
7.3.3              ENDOCRINE TUMORS.. 108
7.3.3.1            THE US DOMINATES THE THERAPEUTIC NUCLEAR MEDICINE MARKET FOR ENDOCRINE TUMOR APPLICATIONS
7.3.4              LYMPHOMA
7.3.4.1            DEVELOPMENT OF NEW ISOTOPES FOR THE TREATMENT OF LYMPHOMA PRESENTS HUGE GROWTH OPPORTUNITIES
7.3.5              OTHER INDICATIONS.. 109

8.... NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET: PROCEDURAL VOLUME ASSESSMENT

8.1             INTRODUCTION
8.2             DIAGNOSTIC PROCEDURES
8.2.1              SPECT PROCEDURES.. 112
8.2.2              PET PROCEDURES
8.3             THERAPEUTIC PROCEDURES
8.3.1              BETA EMITTER PROCEDURES
8.3.2              ALPHA EMITTER PROCEDURES
8.3.3              BRACHYTHERAPY PROCEDURES

9.... NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY REGION

9.1             INTRODUCTION
9.2             NORTH AMERICA
9.2.1              US
9.2.1.1            THE US HOLDS THE LARGEST SHARE OF THE NORTH AMERICAN MARKET
9.2.2              CANADA
9.2.2.1            INVESTMENTS TO SECURE MEDICAL ISOTOPE SUPPLY ARE LIKELY TO BOOST MARKET GROWTH
9.3             APAC
9.3.1              JAPAN
9.3.1.1            JAPAN DOMINATES THE APAC NUCLEAR MEDICINE MARKET
9.3.2              CHINA
9.3.2.1            HIGH INCIDENCE OF CANCER AND STROKES WILL SUPPORT MARKET GROWTH IN CHINA
9.3.3              REST OF ASIA PACIFIC
9.4             EUROPE
9.4.1              GERMANY
9.4.1.1            THE WELL-ESTABLISHED HEALTHCARE SYSTEM IN GERMANY IS A MAJOR FACTOR SUPPORTING MARKET GROWTH IN THE COUNTRY
9.4.2              FRANCE
9.4.2.1            FRANCE HAS A FAVORABLE REIMBURSEMENT SCENARIO FOR NUCLEAR IMAGING
9.4.3              UK
9.4.3.1            RISING DEMAND FOR NUCLEAR IMAGING AND GROWING AWARENESS WILL DRIVE THE MARKET IN THE UK
9.4.4              ITALY
9.4.4.1            GROWING PREVALENCE OF CANCER AND CVD ARE LIKELY TO DRIVE MARKET GROWTH IN ITALY
9.4.5              SPAIN
9.4.5.1            INITIATIVES BY SEMNIM ARE LIKELY TO HAVE A POSITIVE IMPACT ON THE NUCLEAR MEDICINE MARKET IN SPAIN
9.4.6              ROE
9.5             REST OF THE WORLD

10.. COMPETITIVE LANDSCAPE

10.1          OVERVIEW
10.2          MARKET SHARE ANALYSIS
10.3          COMPETITIVE LEADERSHIP MAPPING
10.3.1            VISIONARY LEADERS.. 181
10.3.2            INNOVATORS
10.3.3            DYNAMIC DIFFERENTIATORS
10.3.4            EMERGING COMPANIES
10.4          COMPETITIVE SCENARIO
10.4.1            PRODUCT LAUNCHES & APPROVALS
10.4.2            CONTRACTS
10.4.3            ACQUISITIONS
10.4.4            AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS

11.. COMPANY PROFILES

(BUSINESS OVERVIEW, PRODUCTS OFFERED, RECENT DEVELOPMENTS, MNM VIEW)*
11.1          CARDINAL HEALTH
11.2          CURIUM
11.3          GE HEALTHCARE
11.4          LANTHEUS MEDICAL IMAGING, INC.
11.5          BAYER AG
11.6          BRACCO IMAGING S.P.A.
11.7          ECZACIBAŞI-MONROL NUCLEAR PRODUCTS
11.8          NORDION, INC. (A SUBSIDIARY OF STERIGENICS INTERNATIONAL)
11.9          ADVANCED ACCELERATOR APPLICATIONS (AAA) (A PART OF NOVARTIS)
11.10        NTP RADIOISOTOPES SOC, LTD.
(A SUBSIDIARY OF SOUTH AFRICAN NUCLEAR ENERGY CORPORATION)
11.11        JOINT STOCK COMPANY ISOTOPE (JSC ISOTOPE)
11.12        NORTHSTAR MEDICAL RADIOISOTOPES, LLC.. 208
11.13        ECKERT & ZIEGLER
11.14        JUBILANT DRAXIMAGE, INC. (A SUBSIDIARY OF JUBILANT PHARMA)
11.15        PHARMALOGIC
11.16        INSTITUTE OF ISOTOPES CO., LTD.
11.17        SINOTAU PHARMACEUTICALS GROUP
11.18        ISOTOPIA MOLECULAR IMAGING LIMITED
11.19        SHINE MEDICAL TECHNOLOGIES
11.20        GLOBAL MEDICAL SOLUTIONS, LTD.
11.21        RIGHT TO WIN
*BUSINESS OVERVIEW, PRODUCTS OFFERED, RECENT DEVELOPMENTS, MNM VIEW MIGHT NOT BE CAPTURED IN CASE OF UNLISTED COMPANIES.
12.. APPENDIX

LIST OF TABLES

TABLE 1              NEW REACTORS EXPECTED TO OPEN DURING THE FORECAST PERIOD
TABLE 2              NUCLEAR MEDICINE MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 3              DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 4              DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY REGION,
2017–2024 (USD MILLION)
TABLE 5              NORTH AMERICA: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 6              EUROPE: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 7              APAC: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 8              ALTERNATIVES TO COMMON TC-99M-BASED DIAGNOSTIC PROCEDURES IN
THE FACE OF SEVERE TC-99M SHORTAGES
TABLE 9              SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 10            SPECT RADIOPHARMACEUTICALS MARKET, BY REGION,
2017–2024 (USD MILLION)
TABLE 11            NORTH AMERICA: SPECT RADIOPHARMACEUTICALS MARKET, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 12            EUROPE: SPECT RADIOPHARMACEUTICALS MARKET, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 13            APAC: SPECT RADIOPHARMACEUTICALS MARKET, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 14            TC-99M MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 15            NORTH AMERICA: TC-99M MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 16            EUROPE: TC-99M MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 17            APAC: TC-99M MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 18            I-123 MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 19            NORTH AMERICA: I-123 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 20            EUROPE: I-123 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 21            APAC: I-123 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 22            TI-201 MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 23            NORTH AMERICA: TI-201 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 24            EUROPE: TI-201 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 25            APAC: TI-201 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 26            GA-67 MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 27            NORTH AMERICA: GA-67 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 28            EUROPE: GA-67 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 29            APAC: GA-67 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 30            OTHER SPECT ISOTOPES MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 31            NORTH AMERICA: OTHER SPECT ISOTOPES MARKET, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 32            EUROPE: OTHER SPECT ISOTOPES MARKET, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 33            APAC: OTHER SPECT ISOTOPES MARKET, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 34            PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 35            PET RADIOPHARMACEUTICALS MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 36            NORTH AMERICA: PET RADIOPHARMACEUTICALS MARKET, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 37            EUROPE: PET RADIOPHARMACEUTICALS MARKET, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 38            APAC: PET RADIOPHARMACEUTICALS MARKET, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 39            F-18 MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 40            NORTH AMERICA: F-18 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 41            EUROPE: F-18 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 42            APAC: F-18 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 43            RB-82 MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 44            NORTH AMERICA: RB-82 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 45            EUROPE: RB-82 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 46            APAC: RB-82 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 47            OTHER PET ISOTOPES MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 48            NORTH AMERICA: OTHER PET ISOTOPES MARKET, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 49            EUROPE: OTHER PET ISOTOPES MARKET, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 50            APAC: OTHER PET ISOTOPES MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 51            THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 52            THERAPEUTIC NUCLEAR MEDICINE MARKET, BY REGION,
2017–2024 (USD MILLION)
TABLE 53            NORTH AMERICA: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 54            EUROPE: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 55            APAC: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 56            RA-223 MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 57            NORTH AMERICA: RA-223 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 58            EUROPE: RA-223 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 59            APAC: RA-223 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 60            BETA EMITTERS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 61            BETA EMITTERS MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 62            NORTH AMERICA: BETA EMITTERS MARKET, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 63            EUROPE: BETA EMITTERS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 64            APAC: BETA EMITTERS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 65            I-131 MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 66            NORTH AMERICA: I-131 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 67            EUROPE: I-131 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 68            APAC: I-131 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 69            Y-90 MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 70            NORTH AMERICA: Y-90 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 71            EUROPE: Y-90 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 72            APAC: Y-90 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 73            SM-153 MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 74            NORTH AMERICA: SM-153 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 75            EUROPE: SM-153 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 76            APAC: SM-153 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 77            LU-177 MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 78            NORTH AMERICA: LU-177 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 79            EUROPE: LU-177 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 80            APAC: LU-177 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 81            RE-186 MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 82            NORTH AMERICA: RE-186 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 83            EUROPE: RE-186 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 84            APAC: RE-186 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 85            OTHER BETA EMITTERS MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 86            NORTH AMERICA: OTHER BETA EMITTERS MARKET, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 87            EUROPE: OTHER BETA EMITTERS MARKET, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 88            APAC: OTHER BETA EMITTERS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 89            BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 90            BRACHYTHERAPY ISOTOPES MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 91            NORTH AMERICA: BRACHYTHERAPY ISOTOPES MARKET, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 92            EUROPE: BRACHYTHERAPY ISOTOPES MARKET, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 93            APAC: BRACHYTHERAPY ISOTOPES MARKET, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 94            I-125 MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 95            NORTH AMERICA: I-125 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 96            EUROPE: I-125 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 97            APAC: I-125 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 98            IR-192 MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 99            NORTH AMERICA: IR-192 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 100          EUROPE: IR-192 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 101          APAC: IR-192 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 102          PD-103 MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 103          NORTH AMERICA: PD-103 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 104          EUROPE: PD-103 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 105          APAC: PD-103 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 106          CS-131 MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 107          NORTH AMERICA: CS-131 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 108          EUROPE: CS-131 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 109          APAC: CS-131 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 110          OTHER BRACHYTHERAPY ISOTOPES MARKET, BY REGION,
2017–2024 (USD MILLION)
TABLE 111          NORTH AMERICA: OTHER BRACHYTHERAPY ISOTOPES MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 112          EUROPE: OTHER BRACHYTHERAPY ISOTOPES MARKET, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 113          APAC: OTHER BRACHYTHERAPY ISOTOPES MARKET, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 114          NUCLEAR MEDICINE MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 115          DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 116          SPECT APPLICATIONS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 117          SPECT APPLICATIONS MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 118          SPECT CARDIOLOGY APPLICATIONS MARKET, BY REGION,
2017–2024 (USD MILLION)
TABLE 119          SPECT BONE SCAN APPLICATIONS MARKET, BY REGION,
2017–2024 (USD MILLION)
TABLE 120          SPECT THYROID APPLICATIONS MARKET, BY REGION, 2017–2024 (USD MILLION) 101
TABLE 121          SPECT PULMONARY SCAN APPLICATIONS MARKET, BY REGION,
2017–2024 (USD MILLION)
TABLE 122          OTHER SPECT APPLICATIONS MARKET, BY REGION, 2017–2024 (USD MILLION) 102
TABLE 123          PET APPLICATIONS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 124          PET APPLICATIONS MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 125          PET ONCOLOGY APPLICATIONS MARKET, BY REGION, 2017–2024 (USD MILLION) 104
TABLE 126          PET CARDIOLOGY APPLICATIONS MARKET, BY REGION,
2017–2024 (USD MILLION)
TABLE 127          PET NEUROLOGY APPLICATIONS MARKET, BY REGION, 2017–2024 (USD MILLION) 105
TABLE 128          OTHER PET APPLICATIONS MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 129          THERAPEUTIC APPLICATIONS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 130          THERAPEUTIC APPLICATIONS MARKET, BY REGION, 2017–2024 (USD MILLION) 106
TABLE 131          THERAPEUTIC APPLICATIONS MARKET FOR THYROID INDICATIONS, BY REGION, 2017–2024 (USD MILLION)
TABLE 132          THERAPEUTIC APPLICATIONS MARKET FOR BONE METASTASIS, BY REGION,
2017–2024 (USD MILLION)
TABLE 133          THERAPEUTIC APPLICATIONS MARKET FOR ENDOCRINE TUMORS, BY REGION, 2017–2024 (USD MILLION)
TABLE 134          THERAPEUTIC APPLICATIONS MARKET FOR LYMPHOMA, BY REGION,
2017–2024 (USD MILLION)
TABLE 135          THERAPEUTIC APPLICATIONS MARKET FOR OTHER INDICATIONS, BY REGION, 2017–2024 (USD MILLION)
TABLE 136          NUCLEAR MEDICINE MARKET, BY PROCEDURE,
2017–2024 (THOUSAND PROCEDURES)
TABLE 137          NUCLEAR MEDICINE MARKET, BY REGION,
2017–2024 (THOUSAND PROCEDURES)
TABLE 138          DIAGNOSTIC PROCEDURES MARKET, BY TYPE,
2017–2024 (THOUSAND PROCEDURES)
TABLE 139          DIAGNOSTIC PROCEDURES MARKET, BY REGION,
2017–2024 (THOUSAND PROCEDURES)
TABLE 140          SPECT PROCEDURES MARKET, BY RADIOISOTOPE
2017–2024 (THOUSAND PROCEDURES)
TABLE 141          SPECT PROCEDURES MARKET, BY REGION,
2017–2024 (THOUSAND PROCEDURES)
TABLE 142          PET PROCEDURES MARKET, BY RADIOISOTOPE,
2017–2024 (THOUSAND PROCEDURES)
TABLE 143          PET PROCEDURES MARKET, BY REGION, 2017–2024 (THOUSAND PROCEDURES)
TABLE 144          THERAPEUTIC PROCEDURES MARKET, BY TYPE,
2017–2024 (THOUSAND PROCEDURES)
TABLE 145          THERAPEUTIC PROCEDURES MARKET, BY REGION,
2017–2024 (THOUSAND PROCEDURES)
TABLE 146          BETA EMITTER PROCEDURES MARKET, BY RADIOISOTOPE,
2017–2024 (THOUSAND PROCEDURES)
TABLE 147          BETA EMITTER PROCEDURES MARKET, BY REGION,
2017–2024 (THOUSAND PROCEDURES)
TABLE 148          ALPHA EMITTER PROCEDURES MARKET, BY REGION,
2017–2024 (THOUSAND PROCEDURES)
TABLE 149          BRACHYTHERAPY PROCEDURES MARKET, BY RADIOISOTOPE,
2017–2024 (THOUSAND PROCEDURES)
TABLE 150          BRACHYTHERAPY PROCEDURES MARKET, BY REGION,
2017–2024 (THOUSAND PROCEDURES)
TABLE 151          NUCLEAR MEDICINE MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 152          NORTH AMERICA: NUCLEAR MEDICINE MARKET, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 153          NORTH AMERICA: NUCLEAR MEDICINE MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 154          NORTH AMERICA: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 155          NORTH AMERICA: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 156          NORTH AMERICA: SPECT APPLICATIONS MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 157          NORTH AMERICA: PET RADIOPHARMACEUTICALS MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 158          NORTH AMERICA: PET APPLICATIONS MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 159          NORTH AMERICA: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 160          NORTH AMERICA: BETA EMITTERS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 161          NORTH AMERICA: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 162          NORTH AMERICA: THERAPEUTIC APPLICATIONS MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 163          US: NUCLEAR MEDICINE MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 164          US: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 165          US: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 166          US: SPECT APPLICATIONS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 167          US: PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 168          US: PET APPLICATIONS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 169          US: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 170          US: BETA EMITTERS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 171          US: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 172          US: THERAPEUTIC APPLICATIONS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 173          CANADA: NUCLEAR MEDICINE MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 174          CANADA: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 175          CANADA: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 176          CANADA: SPECT APPLICATIONS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 177          CANADA: PET RADIOPHARMACEUTICALS MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 178          CANADA: PET APPLICATIONS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 179          CANADA: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 180          CANADA: BETA EMITTERS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 181          CANADA: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 182          CANADA: THERAPEUTIC APPLICATIONS MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 183          APAC: NUCLEAR MEDICINE MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 184          APAC: NUCLEAR MEDICINE MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 185          APAC: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 186          APAC: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 187          APAC: SPECT APPLICATIONS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 188          APAC: PET RADIOPHARMACEUTICALS MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 189          APAC: PET APPLICATIONS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 190          APAC: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 191          APAC: BETA EMITTERS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 192          APAC: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 193          APAC: THERAPEUTIC APPLICATIONS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 194          JAPAN: NUCLEAR MEDICINE MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 195          JAPAN: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 196          JAPAN: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 197          JAPAN: SPECT APPLICATIONS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 198          JAPAN: PET RADIOPHARMACEUTICALS MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 199          JAPAN: PET APPLICATIONS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 200          JAPAN: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 201          JAPAN: BETA EMITTERS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 202          JAPAN: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 203          JAPAN: THERAPEUTIC APPLICATIONS MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 204          CHINA: NUCLEAR MEDICINE MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 205          CHINA: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 206          CHINA: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 207          CHINA: SPECT APPLICATIONS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 208          CHINA: PET RADIOPHARMACEUTICALS MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 209          CHINA: PET APPLICATIONS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 210          CHINA: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 211          CHINA: BETA EMITTERS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 212          CHINA: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 213          CHINA: THERAPEUTIC APPLICATIONS MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 214          ROAPAC: NUCLEAR MEDICINE MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 215          ROAPAC: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 216          ROAPAC: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 217          ROAPAC: SPECT APPLICATIONS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 218          ROAPAC: PET RADIOPHARMACEUTICALS MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 219          ROAPAC: PET APPLICATIONS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 220          ROAPAC: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 221          ROAPAC: BETA EMITTERS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 222          ROAPAC: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 223          ROAPAC: THERAPEUTIC APPLICATIONS MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 224          EUROPE: NUCLEAR MEDICINE MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 225          EUROPE: NUCLEAR MEDICINE MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 226          EUROPE: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 227          EUROPE: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 228          EUROPE: SPECT APPLICATIONS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 229          EUROPE: PET RADIOPHARMACEUTICALS MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 230          EUROPE: PET APPLICATIONS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 231          EUROPE: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE,
2017–2024 (USD MILLION)

TABLE 232          EUROPE: BETA EMITTERS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 233          EUROPE: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 234          EUROPE: THERAPEUTIC APPLICATIONS MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 235          GERMANY: NUCLEAR MEDICINE MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 236          GERMANY: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 237          GERMANY: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 238          GERMANY: SPECT APPLICATIONS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 239          GERMANY: PET RADIOPHARMACEUTICALS MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 240          GERMANY: PET APPLICATIONS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 241          GERMANY: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 242          GERMANY: BETA EMITTERS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 243          GERMANY: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 244          GERMANY: THERAPEUTIC APPLICATIONS MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 245          FRANCE: NUCLEAR MEDICINE MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 246          FRANCE: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 247          FRANCE: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 248          FRANCE: SPECT APPLICATIONS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 249          FRANCE: PET RADIOPHARMACEUTICALS MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 250          FRANCE: PET APPLICATIONS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 251          FRANCE: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 252          FRANCE: BETA EMITTERS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 253          FRANCE: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 254          FRANCE: THERAPEUTIC APPLICATIONS MARKET, BY INDICATION,
2017–2024 (USD MILLION)
TABLE 255          UK: NUCLEAR MEDICINE MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 256          UK: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 257          UK: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 258          UK: SPECT APPLICATIONS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 259          UK: PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 260          UK: PET APPLICATIONS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 261          UK: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 262          UK: BETA EMITTERS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 263          UK: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 264          UK: THERAPEUTIC APPLICATIONS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 265          ITALY: NUCLEAR MEDICINE MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 266          ITALY: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 267          ITALY: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 268          ITALY: SPECT APPLICATIONS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 269          ITALY: PET RADIOPHARMACEUTICALS MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 270          ITALY: PET APPLICATIONS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 271          ITALY: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 272          ITALY: BETA EMITTERS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 273          ITALY: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 274          ITALY: THERAPEUTIC APPLICATIONS MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 275          SPAIN: NUCLEAR MEDICINE MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 276          SPAIN: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 277          SPAIN: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 278          SPAIN: SPECT APPLICATIONS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 279          SPAIN: PET RADIOPHARMACEUTICALS MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 280          SPAIN: PET APPLICATIONS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 281          SPAIN: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 282          SPAIN: BETA EMITTERS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 283          SPAIN: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 284          SPAIN: THERAPEUTIC APPLICATIONS MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 285          ROE: NUCLEAR MEDICINE MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 286          ROE: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 287          ROE: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 288          ROE: SPECT APPLICATIONS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 289          ROE: PET RADIOPHARMACEUTICALS MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 290          ROE: PET APPLICATIONS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 291          ROE: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 292          ROE: BETA EMITTERS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 293          ROE: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 294          ROE: THERAPEUTIC APPLICATIONS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 295          ROW: NUCLEAR MEDICINE MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 296          ROW: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 297          ROW: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 298          ROW: SPECT APPLICATIONS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 299          ROW: PET RADIOPHARMACEUTICALS MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 300          ROW: PET APPLICATIONS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 301          ROW: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 302          ROW: BETA EMITTERS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 303          ROW: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 304          ROW: THERAPEUTIC APPLICATIONS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 305          PRODUCT LAUNCHES & APPROVALS (2017–2019)
TABLE 306          CONTRACTS (2017–2019)
TABLE 307          ACQUISITIONS (2017–2019)
TABLE 308          AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS (2017–2019)

LIST OF FIGURES

FIGURE 1            RESEARCH METHODOLOGY: NUCLEAR MEDICINE MARKET
FIGURE 2            RESEARCH DESIGN
FIGURE 3            BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,
AND REGION
FIGURE 4            RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
FIGURE 5            DATA TRIANGULATION METHODOLOGY
FIGURE 6            NUCLEAR MEDICINE MARKET, BY TYPE, 2019 VS. 2024 (USD MILLION)
FIGURE 7            SPECT APPLICATIONS MARKET, BY TYPE, 2019 VS. 2024 (USD MILLION)
FIGURE 8            PET APPLICATIONS MARKET, BY TYPE, 2019 VS. 2024 (USD MILLION)
FIGURE 9            THERAPEUTIC APPLICATIONS MARKET, BY TYPE, 2019 VS. 2024 (USD MILLION)
FIGURE 10          HIGH PREVALENCE OF CANCER TO DRIVE THE MARKET DURING
THE FORECAST PERIOD
FIGURE 11          THE US ACCOUNTED FOR THE LARGEST SHARE OF THE NUCLEAR
MEDICINE MARKET
FIGURE 12          SPECT PROCEDURES TO ACCOUNT FOR THE LARGEST MARKET SHARE DURING THE FORECAST PERIOD
FIGURE 13          BETA EMITTERS TO ACCOUNT FOR THE LARGEST SHARE OF THE THERAPEUTIC NUCLEAR MEDICINE MARKET DURING THE FORECAST PERIOD
FIGURE 14          NUCLEAR MEDICINE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,
AND CHALLENGES
FIGURE 15          NORTH AMERICA TO DOMINATE THE NUCLEAR MEDICINE MARKET IN 2018
FIGURE 16          NORTH AMERICA: NUCLEAR MEDICINE MARKET SNAPSHOT
FIGURE 17          APAC: NUCLEAR MEDICINE MARKET SNAPSHOT
FIGURE 18          KEY DEVELOPMENTS IN THE NUCLEAR MEDICINE MARKET, 2017–2019
FIGURE 19          MARKET SHARE ANALYSIS, BY KEY PLAYER, 2018
FIGURE 20          NUCLEAR MEDICINE MARKET: COMPETITIVE LEADERSHIP MAPPING (2018)
FIGURE 21          CARDINAL HEALTH: COMPANY SNAPSHOT (2018)
FIGURE 22          GE HEALTHCARE: COMPANY SNAPSHOT (2018)
FIGURE 23          LANTHEUS MEDICAL IMAGING, INC.: COMPANY SNAPSHOT (2018)
FIGURE 24          BAYER AG: COMPANY SNAPSHOT (2018)
FIGURE 25          ECKERT & ZIEGLER: COMPANY SNAPSHOT (2018)


掲載企業リスト

プレスリリース

プレスリリース

Memo.png当レポートのプレスリリースは発行されておりません。

資料検索

お探しの資料・レポートをキーワードで検索ください。

当サイト内の検索結果が表示されます。調査レポートは英文目次を掲載しているため、英語検索も有効です。
(ブラウザのスクリプトを有効にしないとサーチエンジンが表示されません)

お問い合わせ

2714110_0.jpg
レポートをお探しいたします。
当サイトに掲載されているレポート以外にも幅広くご提案可能です。レポートの内容に関するご質問、ご確認にも回答いたします。お気軽にお問い合わせください。